posted on 2022-03-09, 22:29authored byChristoph Müller, Jakob Gleixner, Maris-Johanna Tahk, Sergei Kopanchuk, Tõnis Laasfeld, Michael Weinhart, Dieter Schollmeyer, Martin U. Betschart, Steffen Lüdeke, Pierre Koch, Ago Rinken, Max Keller
The recent crystallization of the
neuropeptide Y Y<sub>1</sub> receptor
(Y<sub>1</sub>R) in complex with the argininamide-type Y<sub>1</sub>R selective antagonist UR-MK299 (<b>2</b>) opened up a new
approach toward structure-based design of nonpeptidic Y<sub>1</sub>R ligands. We designed novel fluorescent probes showing excellent
Y<sub>1</sub>R selectivity and, in contrast to previously described
fluorescent Y<sub>1</sub>R ligands, considerably higher (∼100-fold)
binding affinity. This was achieved through the attachment of different
fluorescent dyes to the diphenylacetyl moiety in <b>2</b> via
an amine-functionalized linker. The fluorescent ligands exhibited
picomolar Y<sub>1</sub>R binding affinities (p<i>K</i><sub>i</sub> values of 9.36–9.95) and proved to be Y<sub>1</sub>R antagonists, as validated in a Fura-2 calcium assay. The versatile
applicability of the probes as tool compounds was demonstrated by
flow cytometry- and fluorescence anisotropy-based Y<sub>1</sub>R binding
studies (saturation and competition binding and association and dissociation
kinetics) as well as by widefield and total internal reflection fluorescence
(TIRF) microscopy of live tumor cells, revealing that fluorescence
was mainly localized at the plasma membrane.